
UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Designed to Study Real-World Use of JELMYTO in Low-Grade Upper Tract Urothelial Cancer
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights the presentation of the uTRACT Registry study design at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. The uTRACT Registry is a single-arm, multicenter, prospective and retrospective study evaluating the real-world use of JELMYTO ® (mitomycin) for pyelocalyceal solution for the treatment of adult patients with low-grade upper tract urothelial carcinoma (LG-UTUC) across the United States.
'By capturing these real-world insights, the uTRACT Registry will inform best practices in the management of LG-UTUC,' said Mark Schoenberg, Chief Medical Officer, UroGen. 'This robust data set aims to support the ongoing clinical utility of JELMYTO in managing LG-UTUC, offering new insights into treatment patterns, long-term outcomes, and patient safety in real-world settings.'
As of May 2025, the uTRACT Registry (NCT05874921) has enrolled 274 participants across 22 clinical sites nationwide, with a target enrollment of approximately 400 patients. Of these, about 340 are expected to have LG-UTUC, the population for which JELMYTO is FDA-approved. The study is designed to collect comprehensive data over a three-year period. This includes patient history and baseline disease characteristics prior to initiating treatment with JELMYTO, as well as details on the mode of administration, dosing regimens, surveillance endoscopy findings, and imaging results. Investigators will assess key clinical outcomes such as the presence of no evidence of disease at three months post-treatment, duration of response, recurrence-free survival, time to recurrence or progression, and adverse events.
About JELMYTO
JELMYTO ® (mitomycin) for pyelocalyceal solution is a mitomycin-containing reverse thermal gel containing 4 mg mitomycin per mL gel approved for the treatment of adult patients with LG-UTUC. JELMYTO is a viscous liquid when cooled and becomes a semi-solid gel at body temperature. The drug slowly dissolves over four to six hours after instillation and is removed from the urinary tract by normal urine flow and voiding. It is approved for administration in a retrograde manner via ureteral catheter or antegrade through a nephrostomy tube. The delivery system allows the initial liquid to coat and conform to the upper urinary tract anatomy. The eventual semisolid gel allows for chemoablative therapy to remain in the collecting system for four to six hours without immediately being diluted or washed away by urine flow.
About Upper Tract Urothelial Cancer
Urothelial cancer is the ninth most common cancer globally and the eighth most lethal neoplasm in men in the U.S. Between five percent and ten percent of primary urothelial cancers originate in the ureter or renal pelvis and are collectively referred to as UTUC. In the U.S., there are approximately 6,000 - 7,000 new or recurrent LG-UTUC patients annually. Most cases are diagnosed in patients over 70 years old, and these older patients often have multiple comorbidities. There are limited treatment options for UTUC, with the most common being endoscopic surgery or nephroureterectomy (removal of the entire kidney and ureter). Treatment with endoscopic surgery can be associated with a high rate of recurrence and relapse.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel ® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen's first product to treat LG-UTUC and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on X (Twitter), @UroGenPharma.
APPROVED USE FOR JELMYTO
JELMYTO ® is a prescription medicine used to treat adults with a type of cancer of the lining of the upper urinary tract including the kidney called low-grade Upper Tract Urothelial Cancer (LG-UTUC).
IMPORTANT SAFETY INFORMATION
You should not receive JELMYTO if you have a hole or tear (perforation) of your bladder or upper urinary tract.
Before receiving JELMYTO, tell your healthcare provider about all your medical conditions, including if you:
are pregnant or plan to become pregnant. JELMYTO can harm your unborn baby. You should not become pregnant during treatment with JELMYTO. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JELMYTO. Females who are able to become pregnant: You should use effective birth control (contraception) during treatment with JELMYTO and for 6 months after the last dose. Males being treated with JELMYTO: If you have a female partner who is able to become pregnant, you should use effective birth control (contraception) during treatment with JELMYTO and for 3 months after the last dose.
are breastfeeding or plan to breastfeed. It is not known if JELMYTO passes into your breast milk. Do not breastfeed during treatment with JELMYTO and for 1 week after the last dose.
Tell your healthcare provider if you take water pills (diuretic).
How will I receive JELMYTO?
Your healthcare provider will tell you to take a medicine called sodium bicarbonate before each JELMYTO treatment.
You will receive your JELMYTO dose from your healthcare provider 1 time a week for 6 weeks. It is important that you receive all 6 doses of JELMYTO according to your healthcare provider's instructions. If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment. Your healthcare provider may recommend up to an additional 11 monthly doses.
JELMYTO is given to your kidney through a tube called a catheter.
During treatment with JELMYTO, your healthcare provider may tell you to take additional medicines or change how you take your current medicines.
After receiving JELMYTO:
JELMYTO may cause your urine color to change to a violet to blue color. Avoid contact between your skin and urine for at least 6 hours.
To urinate, males and females should sit on a toilet and flush the toilet several times after you use it. After going to the bathroom, wash your hands, your inner thighs, and genital area well with soap and water.
Clothing that comes in contact with urine should be washed right away and washed separately from other clothing.
JELMYTO may cause serious side effects, including:
Swelling and narrowing of the tube that carries urine from the kidney to the bladder (ureteric obstruction). If you develop swelling and narrowing, and to protect your kidney from damage, your healthcare provider may recommend the placement of a small plastic tube (stent) in the ureter to help the kidney drain. Tell your healthcare provider right away if you develop side pain or fever during treatment with JELMYTO.
Bone marrow problems. JELMYTO can affect your bone marrow and can cause a decrease in your white blood cell, red blood cell, and platelet counts. Your healthcare provider will do blood tests prior to each treatment to check your blood cell counts during treatment with JELMYTO. Your healthcare provider may need to temporarily or permanently stop JELMYTO if you develop bone marrow problems during treatment with JELMYTO.
The most common side effects of JELMYTO include: urinary tract infection, blood in your urine, side pain, nausea, trouble with urination, kidney problems, vomiting, tiredness, stomach (abdomen) pain.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1800FDA1088. You may also report side effects to UroGen Pharma at 1-855-987-6436.
Please see JELMYTO Full Prescribing Information, including the Patient Information, for additional information.
Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: the potential benefits of the uTRACT Registry study, including the nature of the expected data and its ability to help optimize the use of JELMYTO, inform best practices improve patient outcomes, and support the ongoing clinical utility of JELMYTO; the number of patients with LG-UTUC that are expected to enroll in the uTRACT Registry; the estimated patient population and demographics for UTUC; the potential of UroGen's proprietary RTGel technology to improve therapeutic profiles of existing drugs; and UroGen's sustained release technology making local delivery potentially more effective as compared to other treatment options. Words such as 'can,' 'expect,' 'potential,' 'target,' 'will' or other words that convey uncertainty of future events or outcomes are used to identify these forward-looking statements. These statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: prior results may not be indicative of results that may be observed in the future; potential safety and other complications from JELMYTO use in diverse UTUC patient types; the timing and success of clinical trials and potential safety and other complications thereof; unforeseen delays that may impact the timing of progressing clinical trials and reporting data; the ability to obtain regulatory approval within the timeframe expected, or at all; the ability to obtain and maintain adequate intellectual property rights and adequately protect and enforce such rights; complications associated with commercialization activities; labeling limitations; competition in UroGen's industry; the scope, progress and expansion of developing and commercializing UroGen's product and product candidates; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-à-vis alternative therapies or procedures, such as surgery; UroGen's ability to attract or retain key management, members of the board of directors and other personnel; RTGel technology may not perform as expected; and UroGen may not successfully develop and receive regulatory approval of any other product that incorporates RTGel technology. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of UroGen's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 12, 2025, the events and circumstances discussed in such forward-looking statements may not occur, and UroGen's actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to UroGen as of the date of this release.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time Business News
38 minutes ago
- Time Business News
Corrado Garibaldi: The Contrarian Trader Who Profits When Others Panic
In the high-stakes world of Trading Invest Celebrity Italy, where herd mentality often leads to costly mistakes, one investor has built his success on a simple but ruthless principle: When others zig, zag. Corrado Garibaldi—better known in finance circles as Lord Conrad—has carved a reputation as a maverick trader who thrives on going against the grain. His mantra? 'Buy the fear. Sell the euphoria.' The Unconventional Path to Trading Mastery Unlike Wall Street's typical Ivy League-educated financiers, Garibaldi is a self-made trader with no formal finance background. An Italian native, he entered the markets out of necessity, driven by a desire to take control of his financial future. 'I never studied economics or attended business school,' he admits. 'I learned by doing—making mistakes, refining strategies, and realizing that most people lose money because they follow the crowd.' The Contrarian Edge: Why 99.9999% of Traders Are Wrong Garibaldi's core philosophy is rooted in contrarian investing—a strategy that capitalizes on market overreactions. 'When everyone is buying, I'm selling. When panic sets in, I'm buying,' he says. 'The masses are almost always wrong at extremes. That's where the real opportunities lie.' This approach has allowed him to profit from major market swings, whether during the crypto crashes of 2022 or the AI stock frenzy of 2024. Two Sides of the Same Coin: Trader by Day, Investor by Night Garibaldi operates in two distinct modes: As a trader, he's a speed-focused tactician, scalping the Nasdaq and executing swing trades with military precision. As an investor, he's a patient wealth-builder, holding long-term positions in giants like Apple, Microsoft, and Tesla while diversifying into bonds and crypto. His portfolio strategy? 99% long-term holdings, 1% high-octane trading—a balance that maximizes growth while keeping risk in check. The Trader's Mindset: Why Psychology Beats IQ For Garibaldi, trading isn't just about charts—it's about mastering fear and greed. 'Most traders fail because they let emotions drive decisions,' he says. 'The key is to stay mechanical. Follow the plan, not the panic.' He enforces strict rules: ✔ Never risk more than 1% on a single trade ✔ Always use stop-losses ✔ Ignore hype—trade the data, not the narrative 2025 and Beyond: Adapt or Die In an era of AI-driven markets and geopolitical volatility, Garibaldi remains agile—constantly refining strategies and engaging with traders worldwide via social media. 'Markets change. If you're not learning, you're losing,' he warns. Final Word: The Slow Road to Trading Success For aspiring traders, Garibaldi's advice is refreshingly honest: 'This isn't a get-rich-quick game. Consistency beats luck. Small, smart gains compound over time—that's how real wealth is built.' Want to see his strategies in action? Visit Trading Invest Celebrity Italy. TIME BUSINESS NEWS

Yahoo
43 minutes ago
- Yahoo
Mercialys: Acquisition of Saint-Genis 2, a Leading Shopping Center of Greater Lyon
PARIS, June 10, 2025--(BUSINESS WIRE)--Regulatory News: Mercialys (Paris:MERY): An asset perfectly aligned with Mercialys' ambitions Mercialys announces the acquisition of the Saint-Genis 2 shopping center, located in western Lyon, within a catchment area of 700,000 inhabitants—home to the highest-income households in the city. Greater Lyon stands as the second largest consumer market in France after Paris, ahead of Marseille and Toulouse, where Mercialys already holds major assets. This acquisition fully aligns with the Group's strategy to strengthen its presence in the country's most dynamic regions. Acquired for a total price of €146 million including transfer taxes, the asset offers an immediate yield significantly above the Company's investment criteria and presents substantial medium-term value creation potential. A high-performance, leading-retail destination The center had undergone, a few years ago, a comprehensive renovation and environmental performance upgrade program amounting to €45 million. With almost 100 well diversified retail brands and the second most successful hypermarket in the Auchan group (outside the scope of this transaction), it is the largest shopping center in the western part of the Lyon metropolitan area. Beyond its many strengths, the robustness of its catchment area endows this asset with further optimization potential. Its commercial performance can be enhanced through the re-tenanting and consolidation of its retail mix, aligning it with the Company's standards which boast an average occupancy rate of 98% across its 33 strategic assets. An investment initiating a new momentum for the Company This investment represents a unique opportunity for Mercialys to reinforce its position as a key player in the French retail property sector. Guided by a strategy focused on sustainability and operational excellence, the Company intends to fully leverage the strengths of this asset while pursuing its growth objectives. As part of this transaction, Mercialys was advised by Screeb Notarial Office, Arsène for tax matters, and Haldis for technical due diligence. The seller was represented by Michelez Notarial Office, with BNP Paribas and Morgan Stanley acting as financial advisors. This press release is available on presentation of these results is also available online, in the following section:Investors / News and press releases / Financial press releases About Mercialys Mercialys is one of France's leading real estate companies. It is specialized in the holding, management and transformation of retail spaces, anticipating consumer trends, on its own behalf and for third parties. At December 31, 2024, Mercialys had a real estate portfolio valued at Euro 2.8 billion (including transfer taxes). Its portfolio of 1,927 leases represents an annualized rental base of Euro 169.2 million. Mercialys has been listed on the stock market since October 12, 2005 (ticker: MERY) and has "SIIC" real estate investment trust (REIT) tax status. Part of the SBF 120 and Euronext Paris Compartment A, it had 93,886,501 shares outstanding at December 31, 2024. IMPORTANT INFORMATION This press release contains certain forward-looking statements regarding future events, trends, projects or targets. These forward-looking statements are subject to identified and unidentified risks and uncertainties that could cause actual results to differ materially from the results anticipated in the forward-looking statements. Please refer to Mercialys' Universal Registration Document available at for the year ended December 31, 2024 for more details regarding certain factors, risks and uncertainties that could affect Mercialys' business. Mercialys makes no undertaking in any form to publish updates or adjustments to these forward-looking statements, nor to report new information, new future events or any other circumstances that might cause these statements to be revised. View source version on Contacts Analyst and investor Olivier PouteauTel: +33 (0)6 30 13 27 31Email: opouteau@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Virtu Financial Announces Strategic TradeOPS Collaboration, Welcoming First Joint Client
STOCKHOLM and NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Virtu Financial, Inc. (NASDAQ: VIRT), a global leader in trading and execution services, and Limina, a leading provider of cloud-native Investment Management Solutions, are proud to announce a strategic collaboration around Virtu's TradeOPS platform. Virtu's TradeOPS is a streamlined, consolidated platform that covers clients' matching, settlements and payment requirements. Designed and built specifically to automate post-trade workflows, including allocation matching and settlements, exception-based processing in TradeOPS is designed to significantly reduce settlement delays, financial penalties, and workload for buyside firms. Combined with Limina's cloud-native Order and Portfolio Management System (O/PMS), this collaboration enables buyside firms to access a fully-integrated, front-to-back workflow—seamlessly and efficiently. The collaboration has welcomed its first joint client, Cliens, who is now benefiting from Virtu's TradeOPS capabilities using DTCC-CTM via Limina's platform. 'We're excited to work with Limina to deliver an integrated and modern workflow for our TradeOPS clients,' said Pegah Esmaeili, Head of Nordic Region at Virtu. 'This integration supports our mission to deliver scalable, outsourced trading solutions by collaborating with innovative local firms like Limina—allowing us to efficiently extend our market-leading products to clients across the region.' Prem Balasubramanian, Head of Virtu's TradeOPS platform highlighted that recent changes in post-trade settlement, such as the shift to T+1 and the migration from SWIFT MT to MX, have introduced new operational challenges for buyside firms. 'By providing streamlined and effective solutions tailored to clients' needs, we can significantly reduce the operational burden and allow firms to refocus on what truly matters: managing investments and driving performance.' Prem also added, 'Working with Limina is a pleasure. The turnaround has been impressively fast, and we're looking forward to continued collaboration ahead.' "This partnership was an obvious choice to further strengthen the integration capabilities of Limina's Order Management System, not only to DTCC CTM but to all venues that tie into Virtu TradeOPS including SWIFT and more," says Kristoffer Fürst, CEO of Limina. 'The integrated solution that Virtu and Limina offer Cliens helps us extend our straight-through process, giving time to more productive tasks which adds value to our customer,' says Martin Öqvist, CEO of Cliens. About Virtu Financial, is a leading financial services firm that leverages cutting-edge technology to provide execution services and data, analytics and connectivity products to its clients and deliver liquidity to the global markets. Leveraging its global market making expertise and infrastructure, Virtu provides a robust product suite including offerings in execution, liquidity sourcing, analytics and broker-neutral, multi-dealer platforms in workflow technology. Virtu's product offerings allow clients to trade on hundreds of venues across 50+ countries and in multiple asset classes, including global equities, ETFs, foreign exchange, futures, fixed income and myriad other commodities. In addition, Virtu's integrated, multi-asset analytics platform provides a range of pre- and post-trade services, data products and compliance tools that clients rely upon to invest, trade and manage risk across global markets. About LiminaLimina's modern Investment Management Platform helps investment managers increase productivity, decrease cost and manage operational risks through a unified platform spanning the entire investment lifecycle. Founded in 2014, and headquartered in Sweden, Limina serves a growing global client base of institutional asset managers, asset owners and hedge funds with our award-winning cloud-native SaaS offering. About CliensCliens is a Swedish active fund manager focusing on delivering long-term high returns. Our funds and discretionary mandates vary from equity to fixed income and investments are made in Swedish all caps as well as Nordic and Global small caps. Contact: Investor Relations and Media RelationsAndrew Smithmedia@ in to access your portfolio